U.S. Markets closed
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • Dow 30

    34,265.37
    -450.03 (-1.30%)
     
  • Nasdaq

    13,768.92
    -385.08 (-2.72%)
     
  • Russell 2000

    1,987.92
    -36.12 (-1.78%)
     
  • Crude Oil

    84.83
    -0.72 (-0.84%)
     
  • Gold

    1,836.10
    -6.50 (-0.35%)
     
  • Silver

    24.34
    -0.37 (-1.50%)
     
  • EUR/USD

    1.1348
    +0.0031 (+0.2724%)
     
  • 10-Yr Bond

    1.7470
    -0.0860 (-4.69%)
     
  • Vix

    28.85
    +3.26 (+12.74%)
     
  • GBP/USD

    1.3555
    -0.0045 (-0.3321%)
     
  • USD/JPY

    113.6500
    -0.4500 (-0.3944%)
     
  • BTC-USD

    34,629.00
    -3,782.10 (-9.85%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • BEAM
  • SANA
  • Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs.

  • The license does not include any rights to base editing using Cas12b, which remains at Beam. Under the terms of the agreement, Sana will pay Beam an upfront payment of $50 million.

  • Beam is also eligible to receive certain target option exercise fees, certain milestone payments.

  • Earlier today, Beam reported new preclinical data demonstrating the ability of its liver-targeted base editing approach to directly correct R83C, one of the primary disease-causing mutations of glycogen storage disease type Ia (GSDIa).

  • The results demonstrate that newborn huR83C mice treated with Beam's LNP-delivered ABE exhibit normal growth to the end of the study at three weeks of age without any hypoglycemia-induced seizures.

  • In addition, Beam observed editing efficiencies up to approximately 60% by next-generation sequencing of DNA isolated from the whole liver.

  • SVB Leerink initiated coverage on Beam Therapeutics with Outperform rating, with the price target of $117.

  • Related: Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection.

  • Price Action: BEAM shares are up 4.12% at $94.45 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.